SCHEMBL7022301

SCHEMBL7022301

Ic1cccc(SSc2cccc(I)c2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 3/20 0.43
▸ HPGD P15428 2/20 0.43
▸ MGLL Q99685 2/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ MAPT P10636 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ HSP90AA1 P07900 1/20 0.41
▸ IDO1 P14902 2/20 0.37
▸ FAAH O00519 1/20 0.35
▸ APP P05067 3/20 0.34
▸ HIF1A Q16665 2/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ THPO P40225 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ FBP1 P09467 1/20 0.32
▸ METAP2 P50579 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ ALOX15 P16050 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25764826 0.81 — —
SCHEMBL11564509 0.79 — —
SCHEMBL1203597 0.79 — —
SCHEMBL170090 0.75 — —
SCHEMBL23140820 0.74 KDM4E (0.40) MAPTSMN1; SMN2TSHRTDP1
SCHEMBL3480429 0.74 AR (0.36) MGLLIDO1FAAHAPP
SCHEMBL13764455 0.74 ALDH1A1 (0.38) HPGDMGLLMAPTIDO1FAAH
SCHEMBL19416538 0.74 PTGS2 (0.44) CYP1A2IDO1HIF1ACYP2D6CYP2C19
SCHEMBL18408699 0.72 NOTUM (0.37) HSD17B10HPGDCYP1A2MAPTSMN1; SMN2
SCHEMBL21393250 0.72 ACHE (0.44) HPGDMGLLMAPTSMN1; SMN2IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5153305-A From diaryl disulfide; mild conditions using organometallic catalyst RESEARCH INSTITUTE FOR PRODUCTION DEVELOPMENT (JP) 1992-10-06 — — US claimed
US-6646165-B2 Reacting halothiophenol compound with an alkali metal hydroxide to obtain an alkali metal halothiophenolate compound; oxidizing in the presence of a mineral acid to produce bishalophenyl disulfide SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 2003-11-11 — — US disclosed
US-20030060665-A1 Process for producing bishalophenyl disulfide SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 2003-03-27 — — US disclosed
EP-1277731-A1 PROCESS FOR PRODUCING BISHALOPHENYL DISULFIDE SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 2003-01-22 — — EP disclosed
EP-0402481-B1 PRODUCTION OF POLYARYLENE THIOETHER PROD DEV RES INST (JP) 1995-10-25 — — EP disclosed
US-5290911-A Forming polymers by catalytic oxidative coupling RESEARCH INSTITUTE FOR PRODUCTION DEVELOPMENT (JP) 1994-03-01 — — US disclosed
US-5153305-A From diaryl disulfide; mild conditions using organometallic catalyst RESEARCH INSTITUTE FOR PRODUCTION DEVELOPMENT (JP) 1992-10-06 — — US disclosed
US-4983720-A Process for preparing a polyarylene thioether IDEMITSU PETROCHEMICAL CO., LTD. (JP) 1991-01-08 — — US disclosed
EP-0402481-A1 PRODUCTION OF POLYARYLENE THIOETHER RESEARCH INSTITUTE FOR PRODUCTION DEVELOPMENT (JP) 1990-12-19 — — EP disclosed
US-4931542-A Process for preparing a polyarylene thioether IDEMITSU PETROCHEMICAL COMPANY, LIMITED (JP) 1990-06-05 — — US disclosed
EP-0281036-A2 A process for preparing a polyarylene thioether IDEMITSU PETROCHEMICAL CO. LTD. (JP) 1988-09-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060665-A1 Process for producing bishalophenyl disulfide MPST, TST, GRHPR HSD17B10 690/4885HPGD 588/4885MGLL 3929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback